Table 1. Treatment-naive patients who... | American Society of Hematology

Table 1.

Treatment-naive patients who responded to immunotherapy

Patient	Disease duration prior to treatment	Transfusions prior to treatment, no.	Treatment	Interval between treatment and response, mo	Quality of response	Relapse^1-160	MCF ratio
1	2 mo	0	ATG/CSA	3	PR	No	1.4
2	4 mo	12	ATG/CSA	3	PR	No	2.1
3	1 mo	5	ATG/CSA	3	PR	Yes	3.4
4	2 mo	4	ATG/CSA	3	PR	No	1.2^*
5	1 mo	3	ATG/CSA	3	PR	Yes	1.2^*
6	2 mo	4	ATG/CSA	3	PR	Yes	3.4
7	2 mo	4	ATG/CSA	3	PR	Yes	1.4
8	15 d	2	ATG/CSA	3	PR	No	7.4
9	2 mo	7	ATG/CSA	3	PR	Yes	6.7
10	1 mo	2	ATG/CSA	3	PR	No	2.2
11	3 mo	2	CTX/CSA	3	PR	No	3.0
12	2 mo	2	ATG/CSA	3	PR	No	2.3
13	1 mo	4	ATG/CSA	3	PR	Yes	2.4
14	1 mo	0	ATG/CSA	3	PR	Yes	1.5
15	2 mo	4	CTX/CSA	3	CR	Yes	3.5
16	1 mo	6	ATG/CSA	6	PR	Yes	3.0
17	2 mo	4	ATG/CSA	3	CR	No	5.2
18	2 mo	6	ATG/CSA	3	CR	No	0.4^*
19	8 mo	2	CTX/CSA	6	PR	Yes	1.4
20	4 mo	2	ATG/CSA	3	PR	Yes	1.1^*
21	1 mo	1	ATG/CSA	3	PR	No	4.7
22	1 mo	0	ATG/CSA	3	PR	No	2.1
23	4 mo	10	ATG/CSA	3	PR	No	2.0
24	1 y	16	ATG/CSA	3	PR	No	1.9
25	1 mo	6	CTX/CSA	3	PR	No	0.4^*
26	1 mo	3	ATG/CSA	3	PR	No	6.5
27	3 mo	4	ATG/CSA	3	PR	No	1.2^*
28	15 d	2	ATG/CSA	6	PR	No	4.2
29	1 mo	3	ATG/CSA	6	PR	No	7.2
30^*	2 mo	6	ATG/CSA	3	PR	No	1.1^*
31^*	1 y	12	ATG/CSA	3	PR	No	1.1^*
32	15 d	0	ATG/CSA	6	PR	No	5.3
33	9 d	3	ATG/CSA	3	PR	No	2.4
34	1 mo	2	ATG/CSA	3	PR	No	1.0^*
35	15 d	0	ATG/CSA	3	CR	No	2.0
36	2 mo	2	ATG/CSA	3	PR	Yes	1.2^*
37	6 mo	20	ATG/CSA	6	PR	No	1.2^*
38	2 mo	2	ATG/CSA	3	PR	No	4.7

Patient	Disease duration prior to treatment	Transfusions prior to treatment, no.	Treatment	Interval between treatment and response, mo	Quality of response	Relapse^1-160	MCF ratio
1	2 mo	0	ATG/CSA	3	PR	No	1.4
2	4 mo	12	ATG/CSA	3	PR	No	2.1
3	1 mo	5	ATG/CSA	3	PR	Yes	3.4
4	2 mo	4	ATG/CSA	3	PR	No	1.2^*
5	1 mo	3	ATG/CSA	3	PR	Yes	1.2^*
6	2 mo	4	ATG/CSA	3	PR	Yes	3.4
7	2 mo	4	ATG/CSA	3	PR	Yes	1.4
8	15 d	2	ATG/CSA	3	PR	No	7.4
9	2 mo	7	ATG/CSA	3	PR	Yes	6.7
10	1 mo	2	ATG/CSA	3	PR	No	2.2
11	3 mo	2	CTX/CSA	3	PR	No	3.0
12	2 mo	2	ATG/CSA	3	PR	No	2.3
13	1 mo	4	ATG/CSA	3	PR	Yes	2.4
14	1 mo	0	ATG/CSA	3	PR	Yes	1.5
15	2 mo	4	CTX/CSA	3	CR	Yes	3.5
16	1 mo	6	ATG/CSA	6	PR	Yes	3.0
17	2 mo	4	ATG/CSA	3	CR	No	5.2
18	2 mo	6	ATG/CSA	3	CR	No	0.4^*
19	8 mo	2	CTX/CSA	6	PR	Yes	1.4
20	4 mo	2	ATG/CSA	3	PR	Yes	1.1^*
21	1 mo	1	ATG/CSA	3	PR	No	4.7
22	1 mo	0	ATG/CSA	3	PR	No	2.1
23	4 mo	10	ATG/CSA	3	PR	No	2.0
24	1 y	16	ATG/CSA	3	PR	No	1.9
25	1 mo	6	CTX/CSA	3	PR	No	0.4^*
26	1 mo	3	ATG/CSA	3	PR	No	6.5
27	3 mo	4	ATG/CSA	3	PR	No	1.2^*
28	15 d	2	ATG/CSA	6	PR	No	4.2
29	1 mo	3	ATG/CSA	6	PR	No	7.2
30^*	2 mo	6	ATG/CSA	3	PR	No	1.1^*
31^*	1 y	12	ATG/CSA	3	PR	No	1.1^*
32	15 d	0	ATG/CSA	6	PR	No	5.3
33	9 d	3	ATG/CSA	3	PR	No	2.4
34	1 mo	2	ATG/CSA	3	PR	No	1.0^*
35	15 d	0	ATG/CSA	3	CR	No	2.0
36	2 mo	2	ATG/CSA	3	PR	Yes	1.2^*
37	6 mo	20	ATG/CSA	6	PR	No	1.2^*
38	2 mo	2	ATG/CSA	3	PR	No	4.7

PR indicates partial response; CR, complete response.

Cells considered negative for IFN-γ.

Relapse within 2 years of initial response.